Table 2.
Randomized controlled trials
| Study | CT-STAT12 (2011) |
ACRIN13 (2012) |
ROMICAT II14 (2012) |
|||
|---|---|---|---|---|---|---|
| Population | 699 TIMI risk score 0–4 MI 0.9% |
1370 TIMI risk score 0–2 MI 1% |
985 Low–intermediate risk MI 2.5% |
|||
| Randomization | 1:1 | 2:1 | 1:1 | |||
| Control group | SPECT MPI | Usual care | Usual care | |||
| CTA | Controls | CTA | Controls | CTA | Controls | |
| ACS diagnosis | 1.1% | 2.4% | 1% | 1% | 9% | 6% |
| ED discharge | 50% | 23% | 47% | 12% | ||
| ICA rate | 8.0% | 7.4% | 5% | 4% | 12% | 8% |
| Revascularization | 4.3% | 2.7% | 3% | 1% | 6% | 4% |
| Time to diagnosis (median, range) | 2.9 h a (2.1–4.0) | 6.3 h (4–19) | ||||
| Length of stay (median, range) | 18.0 h (8–27) | 24.8 h (19–31) | 23.2 ha | 30.8 h | ||
| One month MACE | 0%a | 0% | 0.4% | 1.2% | ||
| Six months MACE | 0.8% | 0.4% | ||||
| Cost (US$) | 2137b | 3458 | 4026c | 3874 | ||
TIMI, thrombolysis in myocardial infarction.
Statistically significant results in bold.
aPrimary endpoint of the study.
bOnly ED costs.
cIndex hospitalization including angiograms and interventions.